The fFN test is the only named biomarker test recommended in the National Institute for Health and Care Excellence (NICE) clinical guidelines for the risk assessment of preterm labour & birth.1
The NICE guidelines for preterm labour & birth encourage fFN testing to be considered to determine the likelihood of birth within 48 hours for women who are <30 weeks pregnant.1 Further guidelines on the use of biomarker tests to help diagnose preterm labour in women concluded that for women who present at 30 weeks or above, the most appropriate comparator was fFN at a threshold of 50 nanograms/millilitre (ng/ml). For women who present at less than 30 weeks, a treat-all management pathway and fFN testing should be considered to reflect variation in current practice.2
You can download the relevant NICE resources below to learn more.
|Biomarker tests to help diagnose pretermlabour in women with intact membranes
NICE Guidance (July 2018)
|Preterm labour and birth
NICE Guideline (November 2015)
This link will take you to the information intended for healthcare professionals outside of the United States. Because these pages concern the international distribution activities of the QuikCheckTM fFN Test, which are not necessarily governed by US law, contents of the international pages may contain information that does not pertain to US users, including certain products that may not be cleared or approved by US Food & Drug Administration for promotion or sale in the United States. Click “Continue” to proceed, or click “Cancel” to remain in the US site.
Caution: The QuikCheck fFNTest is not sold or offered for sale in the United States or Canada.
Hologic, Inc. does not review nor control the content on non-Hologic websites. This link does not constitute an endorsement by Hologic of the content of the site you are about to visit. Hologic privacy procedures do not apply to the owners of a non-Hologic website.